Skip to content

DISTREPTAZA and pelvic pain

Comparison the impact of DISTREPTAZA and placebo on pelvic inflammatory disease

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20091012002576N52
Enrollment
90
Registered
2025-01-26
Start date
2024-10-22
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic inflammatory disease. Inflammatory disease of uterus, unspecified

Interventions

Intervention 1: Intervention group: Accompanied by standard antibiotics therapy participants are prescribed suppository rectal distreptaza 2g for 9 days,(3 days,TDS, 3days BD,3 days daily) , after whi

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: All patients by pelvic pain and discomfort less than 30 days Pelvic tenderness in vaginal examination Mucoprulant cervicite Absence of pregnancy

Exclusion criteria

Exclusion criteria: Urinary tract infection Tuboovarian abscesses Endometriosis Appendicitis Diverticulitis Hemorrhagic ovarian cyst Ovarian torsion IUD

Design outcomes

Primary

MeasureTime frame
Post infection adhisions. Timepoint: Two weeks after intervention. Method of measurement: By transvaginal sonogram.;Vaginal infection. Timepoint: Two weeks after intervention. Method of measurement: By vaginal examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Davari Tanha

Tehran University of Medical Sciences

Fatedavtanha@gmail.com+98 21 8880 0115

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026